Pirtobrutinib in Patients with Mantle Cell Lymphoma: A Real-World Study in the United States

• Published in: Blood 2024-11, Vol.144, p.7799-7799
• Main Authors: Shah, Nirav N., Winfree, Katherine B., Bhandari, Naleen Raj, Ma, Qinli, He, Dan, Abhyankar, Sarang, Hess, Lisa M.
• Format: Article
• Language: English
• ISSN: 0006-4971
• DOI: 10.1182/blood-2024-199667

Introduction Pirtobrutinib is a highly selective, non-covalent (reversible) Bruton tyrosine kinase inhibitor (BTKi) that has demonstrated promising efficacy and safety in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Pirtobrutinib was approved in the United States for patients with MCL after at least two lines of systemic therapy, including a BTKi, on January 27, 2023, based on data from the BRUIN-18001 Phase 1/2 study. Since the time of this approval, there has been limited real-world data on pirtobrutinib use. This study described characteristics and treatment patterns of patients with MCL who received pirtobrutinib treatment within 15 months after approval in the United States. Methods This observational study used the nationwide Flatiron Health electronic health record-derived de-identified database of patients with MCL. Patients with available line of therapy data who initiated pirtobrutinib between January 27, 2023, and April 30, 2024, were included. Descriptive statistics were used to summarize demographic, clinical, and treatment pattern data. Results Of 82 eligible patients, the majority were male (n=57; 69.5%) and treated in community practice settings (n=51; 63.8%). Patients' median age was 75 years (IQR: 65, 79), median time from diagnosis to initiation of pirtobrutinib was 54.9 months (IQR: 32.7, 94.8), and median follow up time from initiation of pirtobrutinib was 5.4 months (IQR: 2.5, 8.3). Among patients with available data, 24.2% (n=16 of 66) had an ECOG performance status of 2+, 60.8% (n=31 of 51) had Ki-67 index of 30% or more, and 8.5% (n=7) had blastoid or pleomorphic disease. Most received pirtobrutinib as monotherapy (n=62; 75.6%) while the remainder received combination therapy. Median line of therapy of initial pirtobrutinib use was 4 (IQR: 3, 5) with 64.6% (n=53) of patients initiating pirtobrutinib in the 3rd/4th line setting and 19.5% (n=16) receiving it in the 6th line or later. In their treatment history, nearly all patients had received a prior covalent BTKi (cBTKi) (n=77; 93.9%), and 9.8% (n=8) had prior CAR-T therapy. Immediately prior to receiving pirtobrutinib, 34.1% (n=28) of patients were treated with cBTKi monotherapy, 28.0% (n=23) received a cBTKi combination regimen, and 8.5% (n=7) had CAR-T therapy. Among patients who discontinued their initial pirtobrutinib regimen (n=37; 45.1%), CAR-T therapy was the most common treatment received immediately following pirtobrutinib (n=9 of 37; 24.3%). Eig